CAMBRIDGE, Mass., Nov. 16, 2015 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), a computational partner applying quantitative methodologies at critical decision points throughout the drug invention process, announced that it will present and exhibit at the Drug Development Bootcamp on November 17-18, 2015 at The Harvard Club in Boston, MA. This intensive two-day program, organized by Harvard University and Speid & Associates, allows executive level biotech and pharma scientists to share successes and challenges of the drug development process. To maintain an event of this caliber, speakers and participants are limited to those with proven track records of drug development experience.
Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will present a session on modeling and simulation and its application to drug development. Here he will discuss how our approaches to modeling better enabled the selection of a clinical candidate for a bispecific biologic targeting two immune-modulation targets in immunology space, maximizing therapeutic window by tuning affinities and avidities, resulting in a better balance of efficacy and safety. This will be highlighted by participants using a tool that simulates dosing in cyno monkey during the workshop. Modeling and simulation approaches continue to gain momentum in drug development due to their potential to save companies significant costs and shorten research timelines. Dr. Burke will highlight recent results from Applied BioMath's collaborations in biotech and pharma. He will demonstrate how Applied BioMath's modeling approach differs from existing approaches, and how this unique methodology results in prediction approaches, which when validated in the clinic, were proven to be 10x more accurate than accepted industry standards.
"I am very excited to be a part of the Drug Development Boot Camp again, highlighting how our simulation approaches, when applied early, can determine optimal drug properties to enable lead generation and candidate selection. This results in accelerating the development of best in class drugs, saving time, money, and recources."
Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath
About Applied BioMath
Applied BioMath (www.appliedbiomath.com), helps biotech and pharmaceutical companies reduce late stage attrition and accelerate best-in-class (BIC) drugs using quantitative methodologies. Leveraging biology, high performance computing (HPC), proprietary technology and experience in pharma, Applied BioMath delivers biological insights proven to shorten project timelines, lower costs, and develop BIC drugs. Services include knowledge gap analysis, experiment prioritization and design, BIC drug property and tox predictions, indication and patient selection, and optimal clinical trial design and analysis.
Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.
SOURCE Applied BioMath